Document Detail

Statins as adjunctive therapy in the management of hypertension.
MedLine Citation:
PMID:  20512633     Owner:  NLM     Status:  MEDLINE    
The effective optimization of the modifiable risk factors for the development of atherosclerosis is the cornerstone preventive cardiology. Risk factor clustering has been demonstrated to occur in a higher prevalence than would be expected by chance alone. The common cardiovascular risk factors frequently share metabolic pathways. Inflammation and oxidative stress are demonstrable in the major cardiovascular risk factors. Hypertension and dyslipidemia frequently co-exist in an individual. The advent of statin therapy has allowed optimization of the lipid profile and achievement of therapeutic goals advocated by the Adult Treatment Panel of the National Cholesterol Education Program. Statin therapy has been demonstrated to exhibit a wide variety of nonlipid or pleiotropic effects. Observational studies have demonstrated that statin therapy may cause a small but statistically significant alteration of blood pressure. Prospective clinical trials have demonstrated that statin therapy reduces this cardiovascular risk in both hypertensive and normotensive individuals. The potential role of statin therapy in blood pressure reduction is compatible with several pleiotropic mechanisms of statin therapy. However, a significant body of data from prospective, well-designed, controlled clinical trials that have analyzed the effect of statin therapy on blood pressure as the primary end point is lacking. This review examines the observational relationship between hypertension and dyslipidemia, the potential mechanisms by which statin therapy may lower blood pressure, and selected clinical trial data.
Joshua Liao; John A Farmer
Related Documents :
10451033 - The renin-angiotensin system in essential hypertension: associations with cardiovascula...
19491623 - Implementation of new evidence into hypertension guidelines: the case of the ontarget a...
24580463 - Ground-state pressure of quasi-2d fermi and bose gases.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  12     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-07-29     Completed Date:  2010-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  349-54     Citation Subset:  IM    
Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Room 525D, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Dyslipidemias / blood,  complications,  drug therapy*
Endothelium, Vascular / drug effects,  metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypertension / blood,  etiology,  prevention & control*
Vasoconstriction / drug effects
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of device advisories on implantable cardioverter-defibrillator therapy.
Next Document:  Analysis of glycerol dehydrogenase activities present in Mucor circinelloides YR-1.